Genprex announces preclinical data from studies with ONCOPREX

Genprex announced that its research collaborators presented positive preclinical data for the NPRL2 gene. The studies used the Company’s non-viral ONCOPREX Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer, or NSCLC, humanized mouse models and were presented at the 2023 American Association of Cancer Research, or AACR, annual meeting, which took place from April 14-18, 2023 in Orlando, Florida. "We are pleased to have these positive data that support the therapeutic potential of our non-viral delivery system, which is being used in our current REQORSA clinical oncology programs, presented before some of the world’s leading cancer researchers," said Rodney Varner, President and Chief Executive Officer at Genprex. "The use of the ONCOPREX Nanoparticle Delivery System to deliver the NPRL2 tumor suppressor gene positions Genprex to expand our clinical pipeline with a new drug candidate."